Your browser doesn't support javascript.
loading
Good Signal Detection Practices: Evidence from IMI PROTECT.
Wisniewski, Antoni F Z; Bate, Andrew; Bousquet, Cedric; Brueckner, Andreas; Candore, Gianmario; Juhlin, Kristina; Macia-Martinez, Miguel A; Manlik, Katrin; Quarcoo, Naashika; Seabroke, Suzie; Slattery, Jim; Southworth, Harry; Thakrar, Bharat; Tregunno, Phil; Van Holle, Lionel; Kayser, Michael; Norén, G Niklas.
Afiliación
  • Wisniewski AF; AstraZeneca, Macclesfield, UK. antoni.wisniewski@astrazeneca.com.
  • Bate A; Pfizer, Walton-on-the-Hill, Surrey, UK.
  • Bousquet C; INSERM, UMR_S1142, LIMICS, Paris, France.
  • Brueckner A; Department of Public Health and Medical Informatics, CHU University Hospital of Saint Etienne, Saint-Étienne, France.
  • Candore G; Novartis, Basel, Switzerland.
  • Juhlin K; European Medicines Agency, London, UK.
  • Macia-Martinez MA; Uppsala Monitoring Centre, Uppsala, Sweden.
  • Manlik K; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.
  • Quarcoo N; Bayer Pharma AG, Berlin, Germany.
  • Seabroke S; GlaxoSmithKline, London, UK.
  • Slattery J; Medicines and Healthcare Products Regulatory Agency, London, UK.
  • Southworth H; European Medicines Agency, London, UK.
  • Thakrar B; Data Clarity Consulting, Stockport, UK.
  • Tregunno P; F. Hoffmann-La Roche, Basel, Switzerland.
  • Van Holle L; Medicines and Healthcare Products Regulatory Agency, London, UK.
  • Kayser M; GlaxoSmithKline, Wavre, Belgium.
  • Norén GN; Bayer Pharma AG, Wuppertal, Germany.
Drug Saf ; 39(6): 469-90, 2016 06.
Article en En | MEDLINE | ID: mdl-26951233
ABSTRACT
Over a period of 5 years, the Innovative Medicines Initiative PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) project has addressed key research questions relevant to the science of safety signal detection. The results of studies conducted into quantitative signal detection in spontaneous reporting, clinical trial and electronic health records databases are summarised and 39 recommendations have been formulated, many based on comparative analyses across a range of databases (e.g. regulatory, pharmaceutical company). The recommendations point to pragmatic steps that those working in the pharmacovigilance community can take to improve signal detection practices, whether in a national or international agency or in a pharmaceutical company setting. PROTECT has also pointed to areas of potentially fruitful future research and some areas where further effort is likely to yield less.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bases de Datos Factuales / Sistemas de Registro de Reacción Adversa a Medicamentos / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Drug Saf Asunto de la revista: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bases de Datos Factuales / Sistemas de Registro de Reacción Adversa a Medicamentos / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Drug Saf Asunto de la revista: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido